

רופא/ה, רוקח/ת נכבד/ה,

ברצוננו להודיעך על עדכון בעלון לרופא המשותף של התכשירים:

**Solu Medrol 40 mg**

**Solu Medrol 125 mg**

**Solu Medrol 500 mg**

**Solu Medrol 1000 mg**

המרכיב הפעיל:

Solu-Medrol 40 mg:

Methylprednisolone (as methylprednisolone sodium succinate) 40 mg/ Act-O-vial.

Solu-Medrol 125 mg:

Methylprednisolone (as methylprednisolone sodium succinate) 125 mg/ Act-O-vial.

Solu-Medrol 500 mg:

Methylprednisolone (as methylprednisolone sodium succinate) 500 mg/ Vial.

Solu-Medrol 1000 mg:

Methylprednisolone (as methylprednisolone sodium succinate) 1000 mg/ Vial.

**Indicated for:**

Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.

**להלן העדכונים העיקריים בעלון לרופא:**

**4.4 Special warnings and precautions for use**

....

**Musculoskeletal Effects**

An acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (eg, myasthenia gravis) or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (eg, pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriplegia. Elevations of creatine kinase may occur. Cases of rhabdomyolysis have been reported with the use of corticosteroids. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

....

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: <https://reportsideffect.health.gov.il/drugs/home>

....

העלונים המעודכנים נשלחו למשרד הבריאות לצורך פרסומם במאגר התרופות שבאתר משרד הבריאות:  
<https://israel drugs.health.gov.il/#/byDrug>

לחילופין, לקבלת עלונים מלאים מודפסים ניתן לפנות לחברת פייזר פרמצבטיקה ישראל בע"מ  
שנקר 9, ת.ד. 12133, הרצליה, 4672509.  
בברכה,  
עידית שלם אבידר  
רוקחת ממונה